Bank Of America Corp Affimed N.V. Transaction History

Bank Of America Corp

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	SELL	$0.32 - $0.62 $3,194 - $6,190	-9,984 Reduced 84.7%	1,804 $1,000
Q2 2023 Aug 14, 2023	SELL	$0.57 - $1.08 $26,385 - $49,994	-46,291 Reduced 79.7%	11,788 $7,000
Q1 2023 May 12, 2023	SELL	$0.66 - $1.29 $13,402 - $26,196	-20,307 Reduced 25.91%	58,079 $43,000
Q4 2022 Feb 10, 2023	SELL	$1.1 - $2.45 $40,016 - $89,128	-36,379 Reduced 31.7%	78,386 $97,000
Q3 2022 Nov 14, 2022	SELL	$1.96 - $3.32 $27,051 - $45,822	-13,802 Reduced 10.74%	114,765 $236,000
Q2 2022 Aug 12, 2022	SELL	$2.27 - $4.86 $230,872 - $494,291	-101,706 Reduced 44.17%	128,567 $356,000
Q1 2022 May 16, 2022	BUY	$3.69 - $5.65 $698,306 - $1.07 Million	189,243 Added 461.23%	230,273 $1.01 Million
Q4 2021 Feb 08, 2022	SELL	$5.37 - $7.07 $369,133 - $485,991	-68,740 Reduced 62.62%	41,030 $226,000
Q3 2021 Nov 15, 2021	BUY	$5.54 - $7.51 $411,633 - $558,008	74,302 Added 209.49%	109,770 $678,000
Q2 2021 Sep 13, 2021	BUY	$7.78 - $11.4 $275,941 - $404,335	35,468 New	35,468 $302,000

1.09M

Ticker AFMD
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 149,339,008
Market Cap $520M
Description
Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States, Germany, and rest of Europe. Its lead product candidate is AFM13, which has completed Phase II clinical study for peripheral T-cell lymphoma; in Phase IIa clinical trial for CD30-positive lymphoma; and in P...

Get notified when there are updates to the investment portfolio of Bank Of America Corp , based on Form 13F filings with the SEC.

Stay updated on Bank Of America Corp with notifications on news.